Resource impact statement
No significant resource impact is anticipated
NICE has recommended avalglucosidase alfa (AVAL) as an option for treating Pompe disease in babies, children, young people and adults, only if the company provides AVAL according to the commercial arrangement (see section 2 of guidance).
We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year (or approximately £9,000 per 100,000 population, based on a population for England of 56.3m people).
This is because the population size is small with a prevalent population of around 150 people and around 10 new diagnoses of Pompe disease per year in England.
Avalglucosidase alfa has a discount that is commercial in confidence.
This technology is commissioned by NHS England. Providers are NHS hospital trusts.
This page was last updated: